Acronym:
EMBRACE
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Breast, Gynaecological | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Breast/Ovarian |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Sex | Female | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Breast, Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Female |
| Molecular Target | |
| Tumour Stream | Breast/Ovarian |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficiant metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA 1 and BRCA: The EMBRACE study.
Lay Summary
Sponsor / Cooperative group
ANZGOG
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Royal Adelaide Hospital | Anne Milton | anne.milton@sa.gov.au | 08 7074 2342 | Murray | Recruiting |